2023, Number 03
Arrhythmogenic right ventricle cardiomyopathy
Full text
Language: Spanish
References: 16
Page:
PDF size: 201.71 Kb.
ABSTRACT
Arrhythmogenic cardiomyopathies are diseases of the heart muscle with a predisposition to arrhythmias not caused by hypertension, ischemia, or valvular disease. Within this group is arrhythmogenic right ventricular cardiomyopathy which is now also known to be left ventricular. This is a hereditary disease usually autosomal dominant and, in most cases, caused by a mutation in the desmosomes involved in cell union, this causes myocyte death and replacement of these by fibrofatty tissue when stressed. Predisposing to fatal arrhythmias and progression to heart failure mimicking dilated cardiomyopathy. The natural course of the classic disease is characterized by four phases, initially the occult phase manifested exclusively by fatal arrhythmias and sudden death occurs, then there is the electrical alteration in which there are alterations in the electrocardiogram and imaging tests, followed by right ventricular failure and finally biventricular failure. The diagnosis is confirmed using the diagnostic criteria proposed by the International Task Force (ITF), ideally with non-invasive tests or ultimately with invasive tests, then the risk must be stratified to define the treatment, for all patients the restriction of physical activity is essential and for most beta blockers are used, the decision to place an ICD (implantable cardioverter-defibrillator) and use of other antiarrhythmics or ablation is made according to the characteristics of each patient. For patients with suspicion but no confirmed diagnosis, close follow-up for early diagnosis is the most important thing. The prognosis varies with a mortality of 0.08% to 3.6% per year due to heterogeneity in the presentation of the disease.REFERENCES
Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm Society. 2019 [consultado el 1º de diciembre, 2022];16(11):302-37 2. Recuperado a partir de: https://www.hrsonline.org/guidance/clinical-resources/2019-hrs-expert-consensus-statement-evaluation-risk-stratification-and-management-arrhythmogenic
Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, et al. EACVI Scientific Documents Committee, EACVI Board members and external reviewers, Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy—an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging. 2017;18(3): 237-253. DOI: https://doi.org/10.1093/ehjci/jew229
Zeppenfeld K, Tfelt-Hansen J, Riva M, Winkel BG, et al. ESC Scientific Document Group, 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal. 2022 [Consultado Oct 21, 2022];43(40):3997-4126. DOI: https://doi.org/10.1093/eurheartj/ehac262